Enrique Poradosu
2023
In 2023, Enrique Poradosu earned a total compensation of $1.6M as Chief Scientific & Business Officer at Nuvectis Pharma, a 61% increase compared to previous year.
Compensation breakdown
| Bonus | $250,750 |
|---|---|
| Salary | $454,750 |
| Stock Awards | $857,900 |
| Total | $1,563,400 |
Poradosu received $857.9K in stock awards, accounting for 55% of the total pay in 2023.
Poradosu also received $250.8K in bonus and $454.8K in salary.
Rankings
In 2023, Enrique Poradosu's compensation ranked 760th out of 3,006 executives tracked by ExecPay. In other words, Poradosu earned more than 74.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 760 out of 3,006 | 75th |
Division Manufacturing | 437 out of 1,650 | 74th |
Major group Chemicals And Allied Products | 297 out of 918 | 68th |
Industry group Drugs | 291 out of 881 | 67th |
Industry Pharmaceutical Preparations | 192 out of 637 | 70th |
Source: SEC filing on April 29, 2024.
Poradosu's colleagues
We found two more compensation records of executives who worked with Enrique Poradosu at Nuvectis Pharma in 2023.